PCM
RXST icon

Prelude Capital Management’s RxSight RXST Stock Holding History

Prelude Capital Management’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$249K Buy
51,600
+41,600
+416% +$251K 0.02% 871
2026
Q1 		$61.6K Buy
+10,000
New +$83K ﹤0.01% 1108

Other funds holding RXST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NSGL
No Street GP LP San Francisco, California $1.66B AUM 39.91% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Prelude Capital Management's RXST Position: Q2 2026 in Review

Prelude Capital Management increased its RxSight (RXST) stake by 416% in Q2 2026, buying an estimated $251K and bringing the position to 51,600 shares worth $249K. The position accounts for 0.02% of the portfolio, ranked #871.

Prelude Capital Management first reported a position in RXST in Q1 2026 and has held it in 2 quarters since. 151 funds tracked by Wall St. Rank hold RXST as of Q2 2026.

  • Prelude Capital Management held 51,600 shares of RxSight worth $249K as of Q2 2026.
  • Prelude Capital Management bought 41,600 RxSight shares in Q2 2026, an estimated $251K.
  • RxSight made up 0.02% of Prelude Capital Management's portfolio in Q2 2026, its #871 holding.
  • Prelude Capital Management first reported a position in RxSight in Q1 2026 and has held it in 2 quarters since.
  • 151 funds tracked by Wall St. Rank held RxSight as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.